FBC
HZNP

Fairfield, Bush & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Fairfield, Bush & Co’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-33
Closed -$3.39K – 560
2023
Q2 		$3.39K Buy
+33
New +$3.48K ﹤0.01% 390
2022
Q3 		– Sell
-33
Closed -$3K – 513
2022
Q2 		$3K Buy
+33
New +$3.13K ﹤0.01% 385

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fairfield, Bush & Co's HZNP Position: Q3 2023 in Review

Fairfield, Bush & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 33 shares — an estimated $3.39K sold.

Fairfield, Bush & Co first reported a position in HZNP in Q2 2022 and held it in 2 quarters. The position peaked at $3.39K in Q2 2023. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

  • Fairfield, Bush & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • Fairfield, Bush & Co sold 33 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $3.39K.
  • Fairfield, Bush & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022 and held it in 2 quarters.
  • Fairfield, Bush & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.39K in Q2 2023.
  • 485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Fairfield, Bush & Co's 13F filing for Q3 2023, filed 15 Nov 2023.